In December 2021, the FDA granted Emergency Use Authorization for a 5-day course of oral PAXLOVID (nirmatrelvir/ritonavir) to treat COVID-19 in people 12 years old (who weigh at least 40 kg) with mild-to- moderate COVID-19 who are at risk of developing severe illness. Because people with weakened immune systems or other risk factors are more likely to have prolonged or treatment-resistant COVID-19, a longer course of PAXLOVID could be more effective for these patients.
This clinical trial is evaluating if an extended 10- or 15-day course of PAXLOVID is effective and safe for adults and adolescents 12 years of age and older who currently have at least one sign/symptom of COVID-19, and who are immunocompromised.
WHO MAY PARTICIPATE
Joining a clinical trial is an important and personal decision. Thank you for considering this study.
This study may be an option for people who:
- Are 12 years of age or older and weigh at least 40 kg (88 lbs.)
- Have been recently diagnosed with COVID-19 (< 5 days) and currently have at least one symptom of COVID-19
- Are able to swallow tablets
- Are immunocompromised
Note: There are other requirements to participate in this study. A study team member will help determine if this study is right for your family.
To connect with a member of the study team, call 800-887-7002 and provide NCT#: NCT05438602.